You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Hot Topics in Lung Cancer

  • Authors: Ibiayi Dagogo-Jack, MD; Melina Elpi Marmarelis, MD, MSCE; Aadel Chaudhuri, MD, PhD
  • CME / ABIM MOC / CE Released: 3/31/2023
  • Valid for credit through: 3/31/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for physicians, nurses/nurse practitioners (NPs), physician assistants (PAs), and pharmacists.

The goal of this activity is for the learner to be better able to provide expert guidance on important and dynamic topics in lung cancer care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current management of mesothelioma
    • Role of liquid biopsy in lung cancer
  • Demonstrate greater confidence in their ability to
    • Manage patients with lung cancer in light of emerging issues and changing practice patterns (eg, long-term survival, age at diagnosis)


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Ibiayi Dagogo-Jack, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Thoracic Oncologist
    Internal Medicine/Medical Oncology
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Ibiayi Dagogo-Jack, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bayer; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; BostonGene; Genentech; Janssen; Novocure; Pfizer, Inc.; Sanofi/Genzyme; Syros; Xcovery Vision
    Speaker or member of speakers bureau for: Aptitude Health; DAVA Oncology
    Research funding from: Array BioPharma; Genentech; Novartis; Pfizer, Inc.; Vivace

  • Melina Elpi Marmarelis, MD, MSCE

    Assistant Professor
    Division of Hematology/Oncology
    Perelman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Disclosures

    Melina Elpi Marmarelis, MD, MSCE, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Blueprint Pharmaceuticals (former); Bristol Myers Squibb Company (former); Boehringer Ingelheim Pharmaceuticals, Inc.; Ikena Oncology; Janssen (former); Novocure (former); Takeda (former); Thermo Fisher Scientific Inc.
    Research funding from: AstraZeneca; Lilly; Merck; Trizell
    Owns stock (publicly traded) in: bluebird bio, Inc.; Gilead Sciences, Inc.; Merck; Novartis; Pfizer, Inc.; Portola Pharmaceuticals, Inc.
    Other: Medical Writing Support for Novartis

  • Aadel Chaudhuri, MD, PhD

    Assistant Professor of Radiation Oncology
    Cancer Biology Division, Genetics
    Biomedical Engineering and Computer Science & Engineering
    Washington University School of Medicine
    St Louis, Missouri

    Disclosures

    Aadel Chaudhuri, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AlphaSights; AstraZeneca; Daiichi Sankyo, Inc.; DeciBio; Geneoscopy; Guidepoint; Illumina; Roche; Tempus Labs, Inc.
    Patent beneficiary of: Biocognitive Labs; Droplet Biosciences; LiquidCell Dx; Tempus Labs, Inc.
    Stock options from: Geneoscopy

Editor

  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Deborah Grainger, PhD, has no relevant financial relationships.

  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    John Churchwell, PhD, has the following relevant financial relationships:
    Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 Credit™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-23-086-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Hot Topics in Lung Cancer

Authors: Ibiayi Dagogo-Jack, MD; Melina Elpi Marmarelis, MD, MSCE; Aadel Chaudhuri, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/31/2023

Valid for credit through: 3/31/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Management of Mesothelioma in 2023: Updates on Current and Emerging Therapies

Catch up on the state-of-the-art in the management of mesothelioma by hearing from this veteran in the field.
Melina Elpi Marmarelis, MD, MSCE

The Future of Liquid Biopsy: Applications for Early Detection and Non-Metastatic Lung Cancer

Are you up to date on applications for early detection of non-metastatic lung cancer? Get up to speed with this thoughtful presentation.
Aadel Chaudhuri, MD, PhD
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print